Benign Prostatic Hyperplasia Treatment Market Value to Reach Nearly $5 Billion
The value of the global therapeutics market for Benign Prostatic Hyperplasia (BPH) will rise from just over $2 billion in 2014 to approximately $4.9 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 8.23%, according to research and consulting firm GlobalData.
The company’s latest report, OpportunityAnalyzer: Benign Prostatic Hyperplasia – Opportunity Analysis and Forecast to 2024, states that across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, the US will continue its current dominance, accounting for 65% of the global arena by 2024.
Valentina Gburcik, PhD, GlobalData’s Director of Cardiovascular & Metabolic Disorders, states that three novel therapies will contribute to the growth of the BPH therapeutics market, including the launch of Nymox’s novel first-in-class therapy, NX-1207, in the US and Europe in 2017 and 2019, respectively.
Gburcik says “NX-1207 is a direct prostatic injection indicated for patients with moderate-to-severe BPH. It offers an increased safety profile and improved efficacy in comparison with currently available BPH therapies, and lasts for a mean duration of 3.5 years after a single injection. The drug will also be priced at a premium compared with current products, meaning that it will contribute significantly towards the anticipated market expansion following its launch.”
The director adds that an increasing number of diagnosed BPH cases worldwide, resulting from an aging male population, will further drive the market over the forecast period. However, several barriers will hinder any further growth in the BPH therapy space, according to GlobalData’s report.
Gburcik explains “By the end of 2024, various key BPH treatments, such as Jalyn, Avodart, Rapaflo and Cialis, will see their patents expire, followed by subsequent generic erosion. This will be exacerbated by a lack of pipeline therapies for mild-to-moderate BPH symptoms, leaving a significant portion of the patient population underserved.”
This report provides analysis on strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Benign Prostatic Hyperplasia (BPH) therapeutics market. It includes details of the current and future market competition in the global BPH treatment space, and a review of the key industry drivers, restraints and challenges.
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries. For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com. Gain access to our latest press releases and expert analysis on developments in your industry. Subscribe to our RSS feed for the Pharmaceuticals industry, follow our LinkedIn Pharma Showcase Page, or connect with us on: Facebook | LinkedIn | Twitter
Total Page Views: 1699
